Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIPI: Ponatinib Induction then Imatinib in CML
NCT04070443Phase 2Active, not recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Nov 2019
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in chronic myeloid leukemia (CML), sponsored by Centre Léon Bérard. Primary endpoint: Treatment-Free Remission Rate at 36 months. Started Nov 2019; status: active, not recruiting.
02
Drugs
ponatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04070443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04070443.